Cargando…
Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood
BACKGROUND: In preparation for potential clinical development of Ab-01, an antagonistic antibody directed against the IL21R, studies were undertaken to address translational medicine needs that fall into four categories: 1) development of a pharmacodynamic biomarker assay suitable for use in the cli...
Autores principales: | Arai, Maya, Jain, Sadhana, Weaver, Amy A, Hill, Andrew A, Guo, Yongjing, Bree, Andrea G, Smith, Michael F, Allen, Scott W, LaVallie, Edward R, Young, Deborah, Bloom, Laird, Adkins, Karissa, O'Toole, Margot |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892437/ https://www.ncbi.nlm.nih.gov/pubmed/20509950 http://dx.doi.org/10.1186/1479-5876-8-51 |
Ejemplares similares
-
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody
por: Guo, Yongjing, et al.
Publicado: (2010) -
Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys
por: Vugmeyster, Yulia, et al.
Publicado: (2010) -
Publication trends in the medical informatics literature: 20 years of "Medical Informatics" in MeSH
por: DeShazo, Jonathan P, et al.
Publicado: (2009) -
Mapping the Pareto Optimal Design Space for a Functionally Deimmunized Biotherapeutic Candidate
por: Salvat, Regina S., et al.
Publicado: (2015) -
Advances in the Development of Biotherapeutics
por: Oliveira, Pedro H., et al.
Publicado: (2015)